Study characteristics |
Methods |
Randomized, double‐blind trial comparing 5‐aminosalicylic acid and SASP |
Participants |
Male and female participants, aged 19 to 63 years, with acute ulcerative colitis (N = 12) |
Interventions |
1.5 g/day 5‐ASA or 3 g/day SASP for 2 months |
Outcomes |
Clinical endoscopic remission within 2 months of start of therapy was considered as a positive indication of remission induction |
Notes |
Abstract ‐ funding support and conflicts of interest were not reported |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Low risk |
Allocation of drugs was performed using a table of random numbers |
Allocation concealment (selection bias) |
Unclear risk |
Not described |
Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Double‐blind |
Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
Selective reporting (reporting bias) |
Unclear risk |
Not described |
Other bias |
Unclear risk |
Not described |